We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA Rejects EPIX Appeal To Avoid New Trials

Law360 (August 28, 2006, 12:00 AM EDT) -- On Monday, the U.S. Food and Drug Administration denied an appeal from drug maker EPIX Pharmaceuticals Inc. to avoid a second round of trials for Vasovist, an injectible product already approved in Europe for use in magnetic resonance imaging (MRI).

The FDA’s Office of New Drugs suggested in a letter to EPIX that if the company decides to go forward with the additional clinical research, it should conduct two new clinical trials rather than rely on a blinded reread of previously submitted data.

EPIX, based in...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.